Source file signed link, expires in 15 minutes
Extracted text 15
Page 1
No. 01.031/SP/MM/UBC/VII/25
Jakarta, 02 Juli 2025
Kepada yth.
PT Bursa Efek Indonesia
Gedung Bursa Efek Indonesia - Tower 1
Jl. Jend. Sudirman kav 52-53
Jakarta 12190, Indonesia
U.p. Yth. Direktur Penilaian Perusahaan
Otoritas Jasa Keuangan (OJK)
Gedung Sumitro Djojohadikusumo
Jl.Lapangan Banteng Timur 1-4
Jakarta 10710
U.p. Yth. Ketua Eksekutif Pengawas Pasar Modal
Perihal : Hasil Public Expose Tahunan PT UBC Medical Indonesia Tbk (“Perseroan”)
Dengan Hormat,
Dengan ini kami sampaikan bahwa Public Expose Tahunan PT UBC Medical Indonesia Tbk
(“Perseroan”) telah diselenggarakan pada tanggal 30 Juni 2025, pukul 13.30 - 14.30 WIB, di The
Bellezza Suites Permata Hijau Jl. Soepeno No. 34 Jakarta Selatan, Tower Albergo Lantai 7, berdasarkan
ketentuan dari Keputusan Direksi PT Bursa Efek Jakarta Nomor: Kep-306/BEJ/07/2004 dan Surat
Edaran Bursa Efek Indonesia (BEI) Nomor: SE-00003/BEI/05-2020 tanggal 29 Mei 2020 perihal Tata
Cara Pelaksanaan Public Expose secara Elektronik. Peserta yang hadir dalam Daftar Hadir secara
Elektronik dan Daftar Hadir secara Fisik pada acara Paparan Publik (Public Expose) tersebut (tidak
termasuk manajemen dan karyawan Perseroan) adalah masing-masing sebanyak 57 Orang.
Adapun agenda yang dibahas adalah:
1. Pembukaan
2. Paparan Publik tentang profile Perseroan, Pencapaian kinerja 2024, Strategi Usaha, Prospek
Usaha yang disampaikan oleh Bapak Franciscus Xaverius Yoshua R dan Ibu Marcella Angelin
selaku Direktur Utama dan Direktur Perseroan.
3. Tanya Jawab
4. Penutup
Tanya Jawab Penutup Daftar hadir secara Elektronik dan Fisik serta pertanyaan-pertanyaan yang
diajukan oleh peserta yang hadir dan jawaban yang diberikan dalam Public Expose tersebut
sebagaimana terlampir.
Demikian kami sampaikan pemberitahuan ini. Atas perhatian dan kerjasamanya kami ucapkan terima
kasih.
Head Office :
Kawasan Industri Pulogadung
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 2
Page 3
PT UBC Medical Indonesia Tbk
Ringkasan Tanya Jawab Paparan Publik
The Bellezza Suites Permata Hijau Jl. Soepeno No. 34 Jakarta
Selatan, Tower Albergo Lantai 5
Tanggal: 30 Juni 2025
1. Apa yang melatari peningkatan pendapatan perseroan hanya 8% pada 2024 dan apa strategi
perseroan untuk mencapai target di tahun 2025?
Dampak geopolitik Indonesia di tahun 2024 yang sedang dalam pemilu 5 tahunan memiliki
pengaruh yang cukup signifikan terhadap bisnis perseroan yang banyak mengincar proyek yang
akhirnya tertunda ke 2025. Selain itu anak perseroan belum beroperasi secara maksimal
dikarenakan anak perseroan pada 2024 sedang melakukan penambahan produk-produk lokal
baru yang dapat menjadi produk unggulan di masa yang akan datang.
Perseroan cukup optimis terhadap performa perseroan untuk 2025. Hal ini dengan akan
banyaknya realisasi atas proyek – proyek yang tertunda dari 2024 dan juga komitmen
pemerintah untuk meningkatkan standar kesehatan masyarakat. Oleh karena itu perseroan
memiliki keyakinan yang cukup baik terhadap produk, produk yang ditawarkan karena
memiliki reputasi yang baik secara global baik secara produk maupun principal. Selain itu anak
perseroan dengan makin banyaknya produk, produk lokal yang dapat ditawarkan kepada publik
diharapkan dampak memberikan kontribusi yang cukup baik kepada perseroan.
2. Apa rencana operasional perusahaan dalam menghadapi sisa tahun 2025 kalau berkaca atas
hasil 2024?
Kita akan fokus pada efisiensi operasional dan penguatan produk, terutama dengan produk yang
mulai tinggi demandnya dan tentunya dengan margin yang sehat. Perusahaan juga sedang
melakukan evaluasi menyeluruh terhadap proses supply chain agar stok terhadap target
penjualan lebih akurat, dengan hal itu respon kita akan lebih tepat. Kita juga memperhatikan
pertumbuhan jangka panjang dengan membuka sistem kemitraan yang harus berdasarkan
sistem mutualisme yang baik. Sejak awal tahun 2025, perusahaan juga melakukan
pengembangan produk baru yang sesuai dengan kebutuhan sektor kesehatan di Indonesia.
3. Bagaimana strategi pricing yang digunakan agar tetap kompetitif di tengah pasar yang ketat?
Kami tidak sekadar menjual harga, kami menjual nilai. Strategi harga kami berbasis efisiensi
logistik, kemitraan langsung dengan produsen, dan integrasi layanan purna jual. Dengan model
ini, kami bisa menawarkan harga yang kompetitif tanpa mengorbankan kualitas. Bahkan di
segmen premium, kami justru melihat pertumbuhan karena kepercayaan terhadap kualitas
layanan kami dan itu adalah aset utama
4. Apakah ada rencana perusahaan untuk membuat produk dalam negeri lainnya ?
Absolutely. Kami melihat produk dalam negeri bukan hanya sebagai peluang komersial, tetapi
juga sebagai kontribusi strategis terhadap kemandirian alat kesehatan nasional. Saat ini kami
sedang menjajaki kolaborasi dengan mitra luar negeri untuk memproduksi beberapa kategori
alat dengan volume tinggi dan teknologi yang terstandarisasi melalui PT Esora Medika
Indonesia yaitu anak perusahaan kami. Dalam 2–3 tahun ke depan, kami menargetkan 20% dari
portofolio produk kami berasal dari produk dalam negeri yang dibuat oleh PT Esora Medika
Indonesia
Head Office :
Kawasan Industri Pulogadung
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 4
Dokumentasi Public Expose Head Office : Kawasan Industri Pulogadung Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 5
Head Office : Kawasan Industri Pulogadung Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 6
Head Office : Kawasan Industri Pulogadung Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 7
Daftar Hadir Public Expose
30 Juni 2025, Jam : 13.30 – 14.30
Registrasi Public Expose 2025
NO Nama Addres Signature
1 Lucky Suryani Tras News.com Hadir
2 Yameen Cakrawala Media .Com Hadir
3 Nakim Swantara .com Hadir
4 Jiya Putra Jurnal.com Hadir
5 Maya Hasan New Fakta.Com Hadir
6 Linda L Indonesia.com Hadir
7 Indra Jahjono warta loves Hadir
8 Rudi Cakra News .com Hadir
9 Hendra Cosmo Politan .com Hadir
10 Erwin Media Indonesia .Raya Hadir
11 Mayuli s Suara Bayangkara .id Hadir
12 Deasy A Detik 65 Hadir
13 Dina Detik Jakarta Hadir
14 Dini Redaksi .com Hadir
15 Eliesabet Bunga Medika .Com Hadir
16 Andu H GZ post Hadir
17 Andy Sinasindo Hadir
18 Hothida Koran Pelopor Hadir
19 Shopia Radar Berita Nsional Hadir
20 Edo H Sintesa News Hadir
21 Eka S Chakra News Hadir
22 Hartono Analis News Hadir
23 Syarief Coperative Hadir
24 Ismiati Milenium Pos.id Hadir
25 Mulyawan Metronea.net Hadir
26 Supriyanto Metropolitan Post .id Hadir
27 Siti Salamah Jurnal Nusantara Hadir
28 Andi Arif Nusantara Sahabat .Com Hadir
29 Hasan Kompasindo.Com Hadir
30 F Bransa Mulia .Com Hadir
31 Ramelan Metro Headline Hadir
32 Amrul Selaka News Hadir
33 Oemar Karim Suara Keadilan Rakyat Hadir
34 Rio Sinkron.Com Hadir
35 Lucia Bidik Hadir
36 Nurkholis Indonesia Jurnalis.com Hadir
37 Siti Fatimah Azahra Jurnal Nusantara .com Hadir
38 Maya JRA indonesia Hadir
Head Office :
Kawasan Industri Pulogadung
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 8
39 Yudi Pusaka Nasional Hadir
40 Christian Indonesia Time.Net Hadir
41 Wahyu Detik 65.COM Hadir
42 Irwan H Media Patriot .co.id Hadir
43 Roselina Chandra mas .id Hadir
44 Parkile Faktual Net Hadir
45 Fathan JPNN Hadir
46 Nana Warta ekonomi Hadir
47 Dimas Aditya Fajar Harapan id Hadir
48 Puput Insight Media Hadir
49 Fitri Info Aktual Hadir
50 Ghafur Investor Daily Hadir
51 Yuli Kontan Hadir
52 Rizki Emiten News Hadir
53 Abdul Rahim Insight Media Hadir
54 Dinar IDX Channel Hadir
55 AL CNBC Hadir
56 Ilham CNBC Hadir
57 Prasiwi CNBC Hadir
Head Office :
Kawasan Industri Pulogadung
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 9
Subject : Annual Public Expose Results of PT UBC Medical Indonesia Tbk (the "Company")
Respectfully,
We hereby inform you that the Annual Public Expose of PT UBC Medical Indonesia Tbk (the
"Company") has been held on June 30, 2025, at 13.30 - 14.30 WIB, at The Bellezza Suites Permata
Hijau Jl. Soepeno No. 34 South Jakarta, Albergo Tower 7th Floor, based on the provisions of the Decree
of the Board of Directors of PT Jakarta Stock Exchange Number: Kep-306/BEJ/07/2004 and the
Circular Letter of the Indonesia Stock Exchange (IDX) Number: SE-00003/IDX/05-2020 dated May
29, 2020 regarding Procedures for Implementing Public Expose Electronically. The participants who
attended the Electronic Attendance List and Physical Attendance List at the Public Expose event
(excluding the Company's management and employees) were 57 people each.
The agenda discussed was:
1. Unveiling
2. Public Exposure on the Company's profile, 2024 performance achievements, Business
Strategy, Business Prospects delivered by Mr. Franciscus Xaverius Yoshua R and Ms. Marcella
Angelin as President Director and Director of the Company.
3. Frequently Asked Questions
4. Cover
Closing Questions and Answers The list of attendees is Electronic and Physical as well as the questions
asked by the participants present and the answers given in the Public Expose as attached.
Thus we convey this notice. We thank you for your attention and cooperation.
Head Office:
Pulogadung Industrial Estate
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 10
PT UBC Medical Indonesia Tbk
Summary of Public Exposure Q&A
The Bellezza Suites Permata Hijau Jl. Soepeno No. 34 Jakarta
South, Albergo Tower 5th Floor
Date: June 30, 2025
1. What is the background for the company's revenue increase of only 8% in 2024 and what is the
company's strategy to achieve the target in 2025?
The impact of Indonesia's geopolitics in 2024, which is in the 5th annual election, has a
significant influence on the company's business, which is eyeing many projects that are finally
delayed to 2025. In addition, the company's subsidiaries have not yet operated optimally
because the company's subsidiaries in 2024 are adding new local products that can become
superior products in the future.
The company is quite optimistic about the company's performance for 2025. This is with the
many realizations of projects that are delayed from 2024 and also the government's commitment
to improve public health standards. Therefore, the company has quite good confidence in the
products, the products offered because they have a good reputation globally both in terms of
products and principals. In addition, the company's subsidiaries with the increasing number of
products, local products that can be offered to the public are expected to make a good
contribution to the company.
2. What is the company's operational plan to face the rest of 2025 if we reflect on the results of
2024?
We will focus on operational efficiency and product strengthening, especially with products
that are starting to be in high demand and of course with healthy margins. The company is also
conducting a thorough evaluation of the supply chain process so that the stock against the sales
target is more accurate, with that our response will be more appropriate. We also pay attention
to long-term growth by opening a partnership system that must be based on a good mutualism
system. Since the beginning of 2025, the company has also developed new products that suit
the needs of the health sector in Indonesia.
3. What is the pricing strategy used to stay competitive in a tight market?
We don't just sell prices, we sell value. Our pricing strategy is based on logistics efficiency,
direct partnerships with manufacturers, and integration of after-sales services. With this model,
we can offer competitive prices without sacrificing quality. Even in the premium segment, we
are seeing growth due to trust in the quality of our services and that is a key asset
4. Are there any plans for the company to make other domestic products?
Absolutely. We see domestic products not only as a commercial opportunity, but also as a
strategic contribution to the independence of national medical devices. We are currently
exploring collaborations with overseas partners to produce several categories of high-volume
tools and standardized technology through PT Esora Medika Indonesia, our subsidiary. In the
next 2–3 years, we target 20% of our product portfolio to come from domestic products made
by PT Esora Medika Indonesia
Head Office:
Pulogadung Industrial Estate
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 11
Public Expose Documentation Head Office: Pulogadung Industrial Estate Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 12
Head Office: Pulogadung Industrial Estate Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 13
Head Office: Pulogadung Industrial Estate Jl. Rawa Gelam V, Blok. L, Kav.11-13 Jakarta – 13930 (021) 38865110 Info.ubc@ubcindonesia.com www.ubcindonesia.com
Page 14
Public Expose Attendance List
30 June 2025, Hours : 13.30 – 14.30
Public Expose 2025 Registration
NO Name Addres Signature
1 Lucky Suryani After News.com Be present
2 Yameen Media Horizon. Com Be present
3 Nakim Swantara .com Be present
4 Jiya Putra Jurnal.com Be present
5 Maya Hasan New Fakta.Com Be present
6 Linda L Indonesia.com Be present
7 Indra Jahjono Scarlet Witch Be present
8 Rudi Cakra News .com Be present
9 Hendra Cosmo Politan .com Be present
10 Erwin Indonesian Media. Great Be present
11 Mayuli S The Voice of the Shadows.id Be present
12 Deasy A 65 seconds Be present
13 Dina Jakarta Seconds Be present
14 Early Editorial .com Be present
15 Eliesabet Medicinal Flowers. Com Be present
16 Andu H GZ post Be present
17 Andy Synonyms Be present
18 Hothida Pioneer Newspaper Be present
19 Shopia National News Radar Be present
20 Edo H Synthesis News Be present
21 Eka S Chakra News Be present
22 Hartono News Analyst Be present
23 Syarief Co-operative Be present
24 Ismiati Millennium Pos.id Be present
25 São Paulo Metronea.net Be present
26 Supriyanto Metropolitan Post.id Be present
27 Siti Salamah Nusantara Journal Be present
28 Andi Arif Nusantara Sahabat . Com Be present
29 Hasan Kompasindo.Com Be present
30 F Bransa Noble. Com Be present
31 Ramelan Metro Headline Be present
32 Amrul Selaka News Be present
33 Oemar Karim The Voice of People's Justice Be present
34 Rio Sinkron.Com Be present
35 Lucia Aim Be present
36 Nurkholis Indonesia Jurnalis.com Be present
37 Siti Fatimah Azahra Nusantara Journal .com Be present
38 Maya JRA Indonesia Be present
Head Office:
Pulogadung Industrial Estate
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Page 15
39 Yudi National Heritage Be present
40 Christian Indonesia Time.Net Be present
41 Revelation Seconds 65.COM Be present
42 Irwan H Patriot Media co.id Be present
43 Roselina Chandra mas .id Be present
44 Parsley Factual Net Be present
45 Fabio JPNN Be present
46 Nana Economic news Be present
47 Dimas Aditya The Dawn of Hope id Be present
48 Squirt Insight Media Be present
49 Fitri Actual Info Be present
50 Ghafur Investor Daily Be present
51 Yuli Cash Be present
52 Rizki Issuer News Be present
53 Abdul Rahim Insight Media Be present
54 Dinar IDX Channel Be present
55 AL CNBC Be present
56 Inspiration CNBC Be present
57 Squirt CNBC Be present
Head Office:
Pulogadung Industrial Estate
Jl. Rawa Gelam V, Blok. L, Kav.11-13
Jakarta – 13930
(021) 38865110
Info.ubc@ubcindonesia.com
www.ubcindonesia.com
Names mentioned 48 people and organisations named in the text · linked when the evidence is strong
unresolved
person
Franciscus Xaverius Yoshua R
p.1 ×4
unresolved
org
PT Esora Medika Indonesia
p.3 ×2
unresolved
org
PT Esora Medika Indonesia Head Office
p.3 ×2
unresolved
—
Lucky Suryani
p.7 ×2
unresolved
—
Yameen
p.7 ×2
unresolved
—
Nakim
p.7 ×2
unresolved
—
Jiya Putra
p.7 ×2
unresolved
—
Maya Hasan
p.7 ×2
unresolved
—
Linda L
p.7 ×2
unresolved
—
Indra Jahjono
p.7 ×2
unresolved
—
Erwin
p.7 ×2
unresolved
—
Mayuli s
p.7 ×2
unresolved
—
Deasy A
p.7 ×2
unresolved
—
Dina
p.7 ×2
unresolved
—
Dini
p.7
unresolved
—
Eliesabet
p.7 ×2
unresolved
—
Andu H
p.7 ×2
unresolved
—
Hothida
p.7 ×2
unresolved
—
Shopia
p.7 ×2
unresolved
—
Edo H
p.7 ×2
unresolved
—
Eka S
p.7 ×2
unresolved
—
Syarief
p.7 ×2
unresolved
—
Ismiati
p.7 ×2
unresolved
—
Mulyawan
p.7
unresolved
person
Siti Salamah
p.7 ×2
unresolved
—
Andi Arif
p.7 ×2
unresolved
—
F Bransa
p.7 ×2
unresolved
—
Amrul
p.7 ×2
unresolved
—
Oemar Karim
p.7 ×2
unresolved
—
Rio
p.7 ×2
unresolved
—
Lucia
p.7 ×2
unresolved
—
Nurkholis
p.7 ×2
unresolved
person
Siti Fatimah Azahra
p.7 ×2
unresolved
—
Maya
p.7 ×2
unresolved
org
PT Jakarta Stock Exchange
p.9
unresolved
org
Indonesia Stock Exchange
p.9
unresolved
—
São Paulo
p.14
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.